切断
原发性醛固酮增多症
中止
接收机工作特性
化学
泌尿科
内科学
中国人口
人口
曲线下面积
诊断准确性
价值(数学)
医学
醛固酮
统计
免疫分析
作者
Deli Ye,Jing Du,Qianwen Zhang,Yongjian Chen,Xiaofen Yuan,Jun Xia,William Wu,Yu Zhou
摘要
Primary aldosteronism (PA) is a common cause of secondary hypertension, and accurate screening is essential for early detection and intervention. The aldosterone-to-renin ratio (ARR) is the primary screening tool, but most diagnostic laboratories currently rely on immunoassays, which may have limitations in accuracy and reliability. To address this, we investigated the use of liquid chromatography-tandem mass spectrometry (LC-MS/MS) to measure plasma aldosterone concentration (PAC) and plasma renin activity (PRA) and to establish an optimal ARR cutoff value for PA screening. In this study, 123 patients from Zhejiang Provincial People's Hospital in China were recruited, and receiver operating characteristic (ROC) analyses were performed to compare the performance of LC-MS/MS-based ARR with chemiluminescent immunoassay (CLIA)-based ARR. Our results showed that LC-MS/MS outperformed CLIA, achieving an area under the curve (AUC) of 0.899 compared with 0.780. The optimal ARR cutoff value was determined to be 20.8, yielding an AUC of 0.927 with 90.00% sensitivity and 83.50% specificity in a different group of patients (n = 201). Notably, this cutoff remained valid in patients taking calcium channel blockers (CCBs), as PAC and PRA levels did not differ significantly between those treated with CCBs and untreated patients. These findings suggest that LC-MS/MS offers superior diagnostic accuracy for PA screening compared with immunoassays and provide a validated ARR cutoff value of 20.8 that can be applied to the screening of PA in the Chinese Han population. Importantly, the results indicate that discontinuation of CCBs may not be necessary during PA screening, which has practical implications for patient management. Taken together, this study highlights the potential of LC-MS/MS to improve the reliability of PA detection, promote earlier diagnosis, and inform clinical decision-making across different populations.
科研通智能强力驱动
Strongly Powered by AbleSci AI